Silence Therapeutics plc (SLN)

Market Cap	162.45M
Revenue (ttm)	43.26M
Net Income (ttm)	-45.31M
Shares Out	47.22M
EPS (ttm)	-0.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	208,482
Open	3.690
Previous Close	3.690
Day's Range	3.370 - 3.705
52-Week Range	3.190 - 24.380
Beta	1.07
Analysts	Buy
Price Target	40.80 (+1,086.05%)
Earnings Date	May 15, 2025

About SLN

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 116
• Stock Exchange: NASDAQ
• Ticker Symbol: SLN
• Website: https://www.silence-therapeutics.com

Financial Performance

In 2024, Silence Therapeutics's revenue was $43.26 million, an increase of 36.71% compared to the previous year's $31.64 million. Losses were -$45.31 million, -16.45% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for SLN stock is "Buy." The 12-month stock price forecast is $40.8, which is an increase of 1,086.05% from the latest price.

Price Target

$40.8

(1,086.05% upside)

Analyst Consensus: Buy